Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
If we get it effectively FDA saying there is enough evidence here to skip P1b and to enable REGULATORY trial.
I can see the new bus dev guy standing in front of BP and just grinning.
I think the pre-xmas warm up meeting did take place.
However, the telegram group posting it did take place is not proof even if it matches all the input requirements for the magic calculator. Its a self referencing approach that is null and avoid.
The reason i believe it happened is because the content is nothing new and presumably were published to have a positive impact on SP. Hasnt worked.
Good luck to that group and thanks for sharing.
Now to the important stuff. Xmas invites.
"Hands up for Haddock"
Ive heard a rumour. AS is going to invite a select group of LSE posters to a Xmas knees up at the Weatherby Whaler. Not only will there be unlimited amounts of chips but there might be powerpoint slides. Invitees will have to agree to wear Xmas shumpers and bang on about how many shares they have to ensure everyone feels like a "valid" shareholder. Elliot has suggested he utilises his deep and sonourous voice, normally reserved to make a serious answer to a stupid question, to lead the congregation in a rendition of "last christmas". Best of all but yet to be confirmed, Paul Hill and his girlfriend Carol Singers will be there to add some light weight giggling and ensure AS nods enthusiastically.
The organising committee were hoping to repeat the very successful covid pantomime but the chief villian exited stage left astride Spreadsheets the pantomime donkey. You cannot have everything but he sent a very nice postcard, written in crayons and hopes to be back next September
Does anyone know what type of biscuits they had. Im just asking because it influences Spreadsheets
Is it a full moon or has someone grabbed the magic calculator?
Thanks for posting - ill apply ockams razer and assume its accurate.
Not sure what AS is saying about funding. Mentions non-dilutive and then bangs on about US investors. Given he has adopted the word "optionality" then he has it - suggests neither option is close.
Narrowing the trial to a select group in order to increase options of success is standard e.g test fertility drugs in young women with tubular infertility. If a wider licence is granted Drs will assess and use or not. Risk to us is that there are 30+ patients in p1a - we should know where it worked and where it didnt this year.
Finally when his lordship was asked to leave was he directed stage left or stage right. Clip clop, clip clop....
My perception of the self help group has improved due to the meet and the change in members. I might even lend a hand...
Oh hang on
The problem with the continual rampathon is that it is based on made up information that any serious PI can check within minutes. However, it swamps everything else including all the really good stuff- at best it raises awareness but does little that is in-line with genuine LTH. There has to be a reason why the same 4 or so people each need to post several times per day. Im guessing they are either suffering from a strange form of OCD or they are on the make. If they stopped i think SP would go up.
Compare there efforts to a much wider group come publication of P1a. Im booking my twitter slots now.
RaH would be proud though. Excellent use of the magic calculator.
I'm torn - AS hasn't delivered to a stated date yet but also had knowledge of who was lined up for C7. Added to that the number of centres now involved should facilitate recruitment.
I'm thinking Xmas to start buying What Car magazine again
Indy I'm worried that one of your secret packages is leaking intimate a cavity....
What! Over? Did you say over?
Nothing is over until WE decide it is. Was it over when the germans bombed pearl harbour. Hell no
US has turned inter web on. Phew
Timster - nooooooooooooooooo
To be fair says nothing is top notch. Also says efficacy data is top notch. Not sure how regulators define top notch but I'm pretty sure it is more than an n of 1 and will have some sort of statistics in there. Will run out of superlatives by the time avacta get a randomised study with incredible confidence intervals and hugely clinically significant result. I'm also more confident than ever but more because of the studies designs being proposed and my interpretation that means it works. Not proof just my interpretation.
Isn't normal dox the normal first line treatment. For ethics to grant that they must be reasonably confident patients in the trial have a reasonable chance of not suffering any detriment and either them and/or the health system a reasonable chance of a benefit. To be able to reason that they would need data.
Sheppy - healthy skeptisimn is what the board should be about but to call avacta a pure gamble yet quote the market perception has being relevant suggests you are confused. Either all shares are a coin toss or all shares are bound by the market. If its the later then the rules of high risk, high return apply but then that's not a pure gamble but a calculated one.
Nah - never go back and I had a mk2, mk3 and sat in a few XR3i. Thinking XKR has a balance between the possibilities. However, there is a nice Reliant Scimitar up for grabs that would suit the Timster. No rust so you know its a bargain.
In respect of recovery its a difficult one. Cardiac cells don't regenerate but there may be effects below this threshold. Are those effects reversible - in other cells and drugs yes but I'm not sure with cardiac cells.
The doctors couldn't tell is also great. Were they referring to visible appearance, basic signs or something more like blood tests. How many patients etc etc. They keep upping the dose which suggests cardiac toxicity is known to remain low otherwise unethical to continue - I'm thinking they are looking to see the same thing at more frequent dosing. The trial will enable that statement to be proven and therefore allowed as a claim. As I say my belief is they can already predict the outcome hence run in parallel - the two week cycle trial is to keep regulators and ethics committees happy ready to crack on with the efficacy P2 study.
Roll on Xmas (which may happen between St nicholas and St Davids days. 🤔.
Trying to decide between new car or something classic
When I say looking for I mean looking for an absence of....
At the risk of joining the magic calculator brigade AS has said the starting dose for the first cohort for two weekly dosing will be lower then C7 and then escalate up. It remains a P1 study suggesting tolerability remains key variable. I'm going to guess they looking for early markers of toxity and cumulative dose. Each six weeks patients will be on 50% bigger dose compared to three weeks and have less recovery time. However, they must have pretty good idea of what they expect to see due to the short timeframe. They know two week dosing also hits tumour harder and avoids saturating the fap enzyme maximising bang per mg. Otherwise why not just continue with ever increasing three weekly dosing. Its getting exciting - if they hadn't got positive results why would you plan a whole new study and move P2 forwards. Conjecture and assumption not proof. Anyone want to borrow a magic calculator.
Live. They have several highly qualified scientist including new medical director. I suspect AS might delegate much of the data report writing to them whilst they have repeated debates amongst themselves and the investigators about who gets to be first author of the paper that is already 2/3s written.